Langsung ke konten

Onkologi (Anak)

Imunoterapi

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (terbuka di window baru)

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS

Sumber‎: N Engl J Med 2017;376(9):836-47.

Index‎: PubMed 28249141

DOI‎: 10.1056/NEJMoa1609783

https://www.ncbi.nlm.nih.gov/pubmed/28249141 (terbuka di window baru)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (terbuka di window baru)

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

Sumber‎: N Engl J Med 2014;371(16):1507-17.

Index‎: PubMed 25317870

DOI‎: 10.1056/NEJMoa1407222

https://www.ncbi.nlm.nih.gov/pubmed/25317870 (terbuka di window baru)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (terbuka di window baru)

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA

Sumber‎: N Engl J Med 2018;378(5):439-48.

Index‎: PubMed 29385370

DOI‎: 10.1056/NEJMoa1709866

https://www.ncbi.nlm.nih.gov/pubmed/29385370 (terbuka di window baru)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (terbuka di window baru)

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE

Sumber‎: Cancer 2013;119(22):4036-43.

Index‎: PubMed 24006085

DOI‎: 10.1002/cncr.28334

https://www.ncbi.nlm.nih.gov/pubmed/24006085 (terbuka di window baru)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (terbuka di window baru)

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S

Sumber‎: Clin Cancer Res 2016;22(8):1951-7.

Index‎: PubMed 26644412

DOI‎: 10.1158/1078-0432.CCR-15-1349

https://www.ncbi.nlm.nih.gov/pubmed/26644412 (terbuka di window baru)

ONKOLOGI (ANAK)
Imunoterapi
Indonesia
Imunoterapi
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Hubungi Perwakilan Setempat dari Panitia Penghubung Rumah Sakit

Layanan gratis sedunia, tersedia 24 jam setiap hari bagi para dokter yang menangani Saksi-Saksi Yehuwa.

Kontak

Paket Informasi Medis

Topiknya antara lain: Strategi klinis untuk menangani perdarahan dan anemia tanpa transfusi darah, etika dan pendirian Saksi-Saksi Yehuwa tentang perawatan medis, dan pelayanan yang diberikan Saksi Yehuwa kepada dunia medis melalui jaringan Panitia Penghubung Rumah Sakit di seluruh dunia.

Download

Video

Video: Pilihan perawatan maupun pertimbangan dalam hal kesehatan dan etika bagi dokter yang merawat Saksi-Saksi Yehuwa.

Lihat Video